Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab Dosing Durations in Thyroid Eye Disease
NCT05002998Phase 4Completed
- Sponsor
- Amgen
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 4 trial of teprotumumab in thyroid eye disease (TED), sponsored by Amgen. Started Sep 2021; status: completed.
02
Drugs
teprotumumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05002998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002998.